Skip directly to content


Pfizer Australia is a significant contributor to scientific discovery in Australia from early discovery through to capability development. Pfizer Australia works with some of Australia's best and brightest scientists, clinicians and investigators to discover and develop new medicines to prevent, treat and cure human diseases. 

Clinical Research

Pfizer is a significant contributor to the conduct of clinical trials in Australia. Clinical trials are human tests that help doctors understand if a new medicine is more effective or safer than existing medicines or treatments, and to determine the appropriate dosage of the new medicine. 

Results from clinical trials can lead to the development of medicines that can prevent death and also improve the lives of people suffering from a diverse range of challenging medical conditions.


Supporting Australian scientists

In Australia, Monash University became the first academic institution outside the United States to join Pfizer’s network of research partners in the CTI network. In 2015 Pfizer also formed a partnership with the University of Queensland (UQ) to advance drug discovery in Australia. The agreement with UniQuest, UQ’s commercialisation arm, is focussed on vaccines, oncology, infectious diseases, peptides and advanced imaging, inflammation and immunology, and neuroscience and pain.

A third partnership was formed with the University of Melbourne in 2016, which has strong capabilities in the areas of neuroscience, infection, inflammation and immunity, and oncology.

Centre for Therapeutic Innovation

The Centers for Therapeutic Innovation (CTI) facilitate authentic collaboration between Pfizer scientists and select academic medical centres, disease foundations, and the National Institutes of Health. The aim is to translate promising science into clinical candidates. Pfizer Inc. has CTI labs in San Francisco, New York, Boston and San Diego.

These state-of-the-art laboratories are populated with Pfizer scientists and post-docs who are creating and advancing novel therapeutics, with the goal of moving the therapeutics rapidly into first-in-human proof of mechanism studies. CTI’s research collaborators work side-by-side with Pfizer scientists in the discovery and development of new therapies for unmet medical needs. For more information visit:

Unprecedented Access and Authentic Collaboration

As part of the CTI, an entrepreneurial group within Pfizer partners with leading academic centres and disease foundations with the aim of translating promising science into clinical candidates. Partners are given unprecedented access to our antibody/small molecule library and technologies, and can draw upon Pfizer’s expertise.

Authentic collaboration includes:

  • shared decision making

  • shared accountability

    • each project is overseen by a joint steering committee to evaluate the success of the program and monitor progress toward milestones

  • alignment on incentives

    • joint IP and ownership, broad rights to publication, milestone payments and royalties for successful programs